Therapy insight: Osteoporosis during hormone therapy for prostate cancer

Nature Clinical Practice Urology

Volumn 2, Issue 12, 2005, Pages 608-615

  Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Fracture; GnRH agonist; Osteoporosis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTRADIOL; ESTROGEN; GONADORELIN AGONIST; LEUPRORELIN; MONOCLONAL ANTIBODY; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CANCER HORMONE THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ESTROGEN DEFICIENCY; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOGONADISM; MALE; OSTEOLYSIS; OSTEOPOROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VERTEBRA FRACTURE;

EID: 31344449077     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1016/j.joca.2005.01.008     Document Type: Article

References (66)

1. National Osteoporosis Foundation. Men and Osteoporosis [http://www.nof.org/men/index.htm] (accessed 28 September 2005)
2. Seeman E (1999) The structural basis of bone fragility in men. Bone 25: 143-147
3. Bilezikian JP (1999) Osteoporosis in men. J Clin Endocrinol Metab 84: 3431-3434
4. Orwoll ES (1998) Osteoporosis in men. Endocrinol Metab Clin North Am 27: 349-367
5. Gardsell P et al. (1990) The predictive value of forearm bone mineral content measurements in men. Bone 11: 229-232
6. van der Klift M et al. (2002) The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 17: 1051-1056
7. Cummings SR et al. (1990) Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 263: 665-668
8. Kanis JA et al. (1994) The diagnosis of osteoporosis. J Bone Miner Res 9: 1137-1141
9. Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736-746
10. Szulc P et al. (2000) Cross-sectional assessment of age-related bone loss in men: The MINOS study. Bone 26: 123-129
11. Snyder PJ et al. (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85: 2670-2677
12. Zojer N et al. (1999) Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21: 389-406
13. Zmuda JM et al. (2000) Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 15: 1417-1424
14. Finkelstein JS et al. (1994) A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia. J Clin Endocrinol Metab 78: 724-730
15. Grampp S et al. (1993) Radiologic diagnosis of osteoporosis. Current methods and perspectives. Radiol Clin North Am 31: 1133-1145
16. Schutte HE and Park WM (1983) The diagnostic value of bone scintigraphy in patients with low back pain. Skeletal Radiol 10: 1-4
17. Smith MR et al. (2004) Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer [abstract]. J Clin Oncol (Proc ASCO Ann Mtg) 22 (Suppl): 4507
18. Shahinian VB et al. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154-164
19. Smith M et al. Risk of clinical fracture after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol, in press
20. Daniell HW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157: 439-444
21. Townsend MF et al. (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79: 545-550
22. Hatano T et al. (2000) Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86: 449-452
23. Oefelein MG et al. (2001) Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724-1728
24. Melton LJ III et al. (2003) Fracture risk following bilateral orchiectomy. J Urol 169: 1747-1750
25. Dickman PW et al. (2004) Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 172: 2208-2212
26. Diamond T et al. (1998) The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83: 1561-1566
27. Maillefert JF et al. (1999) Bone mineral density in me treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161: 1219-1222
28. Daniell HW et al. (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163: 181-186
29. Smith MR et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948-955
30. Berruti A et al. (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167: 2361-2367
31. Smith MR et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008-2012
32. Smith MR et al. (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J Clin Endocrinol Metab 89: 3841-3846
33. Lee H et al. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer, in press
34. Leder BZ et al. (2001) Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 86: 511-516
35. The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 1281-1286
36. Garnick MB (1986) Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer: Results of a prospectively randomized trial. Urology 27: 21-28
37. Need AG et al. (1996) Vitamin D receptor genotypes are related to bone size and bone density in men. Eur J Clin Invest 26: 793-796
38. Eriksen EF et al. (1988) Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241: 84-86
39. Oursler MJ et al. (1994) Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 91: 5227-5231
40. Falahati-Nini A et al. (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106: 1553-1560
41. Leder BZ et al. (2003) Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88: 204-210
42. Slemenda CW et al. (1997) Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100: 1755-1759
43. Khosla S et al. (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83: 2266-2274
44. Greendale GA et al. (1997) Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res 12: 1833-1843
45. Eriksson S et al. (1995) Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57: 97-99
46. Scherr D et al. (2002) Diethylstilbesterol revisited: Androgen deprivation, osteoporosis and prostate cancer. J Urol 167: 535-538
47. Orwoll E et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604-610
48. Dawson-Hughes B et al. (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670-676
49. Giovannucci E et al. (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58: 442-447
50. Chan JM et al. (1998) Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9: 559-566
51. 2 vitamin D in relation to prostate cancer: A hypothesis. Cancer Causes Control 9: 567-582
52. Diamond TH et al. (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study. Cancer 92: 1444-1450
53. Reid IR et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653-661
54. Boyle WJ et al. (2003) Osteoclast differentiation and activation. Nature 423: 337-342
55. Bekker PJ et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059-1066
56. Taxel P et al. (2002) The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 87: 4907-4913
57. Balfour JA and Goa KL (1998) Raloxifene. Drugs Aging 12: 335-342
58. Delmas PD et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647
59. Ettinger B et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645
60. Steiner MS et al. (2004) Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer [abstract]. J Clin Oncol (Proc ASCO Ann Mtg) 22 (Suppl): 4597
61. Verhelst J et al. (1994) Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 41: 525-530
62. Sieber PR et al. (2002) Bone mineral density is maintained during bicalutamide ('Casodex') treatment [abstract #783]. Proc 2002 ASCO Ann Mtg [http://www.asco.org/ac/ 1,1003,_12-002636-00_18-0016-00_19-00783,00.asp] (accessed 28 September 2005)
63. Smith MR et al. (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition. J Clin Oncol 22: 2546-2553
64. Diamond TH et al. (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer 100: 892-899
65. Bae DC and Stein BS (2004) The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 172: 2137-2144
66. Cummings SR et al. (1993) Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341: 72-75